Skip to content

Corvus Pharmaceuticals

US · CRVS #3339 by market cap Listed 2016
10.41 -0.15 -1.42%
Live - 5344 symbols - heartbeat 323s ago · 2026-10-08 08:12
Pre-market 10.13 -2.69%
After-hours 10.52 +1.06%
Market cap
875.70M
P/B
3.89
EPS
-0.53
Reader sentiment Are you bullish or bearish on CRVS?

Anonymous reader poll. Unscientific, not investment advice.

Corvus Pharmaceuticals shares were changing hands at 10.41, down 1.42% on the day. That leaves the company valued at approximately 875.70M, the #3339 most valuable US-listed company we track. Wall Street's 4-analyst consensus lands on Buy, with a price target averaging 29.50 (+183% from here). Against a 52-week band of 6.39-26.95, the shares are currently 20% of the way up.

✦ StockVane Quant Insights how this is computed

Quant Rating C Preliminary
  • Not yet in the StockVane Momentum strategy's universe - this name needs price history back to 2021 for a reliable signal and doesn't have it yet (most often because it IPO'd or was spun off more recently). This grade is a preliminary blend of valuation, momentum and analyst data, not a Momentum buy/sell call.
  • Valuation sits at the 36% percentile of its own 5-year range.
  • Price momentum averages +9.1% across the trailing 3-month/1-year windows.
  • Analyst consensus across 4 analysts is Buy.
Quant Sentiment Bullish
  • Recent price momentum is +9.1% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 20.4% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Price chart

17.8510.4110.412026-04-092026-10-07
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60

Performance

1W -9.64%
1M -27.66%
3M -33.40%
6M -27.46%
YTD +35.19%
1Y +51.53%
3Y +598.66%
5Y +113.76%

Key statistics

Price & volume

Prev close
10.56
Open
10.25
Day range
10.25 - 10.65
Avg price
10.47
Volume
1.16M
Turnover
12.11M
Amplitude
3.74%
52-week range
6.39 - 26.95

Valuation

P/E
-19.64
P/E (TTM)
-16.27
P/B
3.89
EPS
-0.53
Net profit
-44.58M
Net assets
225.36M

Share structure

Market cap
875.70M
Float cap
757.73M
Shares out
84.12M
Float shares
72.79M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2016-03-23
52-week range 20% of range
6.39 26.95

61.4% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-7.98M net over the window

Short interest

Shares short
17.18M
As of
2026-09-15

Frequently asked questions

What is the current stock price of Corvus Pharmaceuticals (CRVS)?

Corvus Pharmaceuticals last traded at 10.41. The quote on this page refreshes every few seconds while US markets are open.

What is Corvus Pharmaceuticals's market cap?

About 875.70M.

What is the P/E ratio of Corvus Pharmaceuticals?

The trailing twelve-month P/E is -16.27. The Valuation tab shows it against the stock's own five-year range.

Does Corvus Pharmaceuticals pay a dividend?

Corvus Pharmaceuticals does not currently pay a regular dividend.

Is Corvus Pharmaceuticals a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 29.50, which implies 183.4% upside from the current price. This is not investment advice.

Quote time 2026-10-08 08:12:11 · For reference only, not investment advice and not tailored to your situation.